These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19563311)

  • 21. Dilemmas in regulation of the market for pharmaceuticals.
    Maynard A; Bloor K
    Health Aff (Millwood); 2003; 22(3):31-41. PubMed ID: 12757269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK.
    Atella V; Schafheutle E; Noyce P; Hassell K
    Appl Health Econ Health Policy; 2005; 4(1):23-35. PubMed ID: 16076236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost sharing, caps on benefits, and the chronically ill--a policy mismatch.
    Thorpe KE
    N Engl J Med; 2006 Jun; 354(22):2385-6. PubMed ID: 16738277
    [No Abstract]   [Full Text] [Related]  

  • 24. Troubled by health plans' high cost-sharing for drugs.
    Castellani J; Lee J
    Mod Healthc; 2015 Feb; 45(8):30-1. PubMed ID: 25823211
    [No Abstract]   [Full Text] [Related]  

  • 25. A survey of eyecare affordability among patients seen in collaborative care in Australia and factors contributing to cost barriers.
    Cheung R; Ly A
    Public Health Res Pract; 2024 Jun; 34(2):. PubMed ID: 38889914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using clinically nuanced cost sharing to enhance consumer access to specialty medications.
    Buxbaum J; de Souza J; Fendrick AM
    Am J Manag Care; 2014 Jun; 20(6):e242-4. PubMed ID: 25180506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inadequate prescription-drug coverage for Medicare enrollees--a call to action.
    Soumerai SB; Ross-Degnan D
    N Engl J Med; 1999 Mar; 340(9):722-8. PubMed ID: 10053183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Policy challenges of nanomedicine for Australia's PBS.
    Faunce TA
    Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The community safety net and prescription drug access for low-income, uninsured people.
    Felland LE; Taylor EF; Gerland AM
    Issue Brief Cent Stud Health Syst Change; 2006 Apr; (105):1-4. PubMed ID: 16685778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Affordability of health care under publicly subsidized insurance after Massachusetts health care reform: a qualitative study of safety net patients.
    Zallman L; Nardin R; Malowney M; Sayah A; McCormick D
    Int J Equity Health; 2015 Oct; 14():112. PubMed ID: 26511222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incremental change in the Australian health care system.
    Hall J
    Health Aff (Millwood); 1999; 18(3):95-110. PubMed ID: 10388206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Policy Option to Enhance Access and Affordability for Medicare’s Low-Income Beneficiaries.
    Schoen C; Davis K; Willink A; Buttorf C
    Issue Brief (Commonw Fund); 2018 Sep; 2018():1-15. PubMed ID: 30211508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
    Davis MM; Patel MS; Halasyamani LK
    J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of cost-sharing in private health insurance on the utilization of health care services between private insurance purchasers and non-purchasers: a study of the Korean health panel survey (2008-2012).
    Choi Y; Kim JH; Yoo KB; Cho KH; Choi JW; Lee TH; Kim W; Park EC
    BMC Health Serv Res; 2015 Oct; 15():489. PubMed ID: 26510421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailoring access to high cost, genetically targeted drugs.
    Hall WD; Ward R; Liauw WS; Lu CY; Brien JA
    Med J Aust; 2005 Jun; 182(12):607-8. PubMed ID: 15963014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing Branded Prescription Drug Prices: A Review of Policy Options.
    Alexander GC; Ballreich J; Socal MP; Karmarkar T; Trujillo A; Greene J; Sharfstein J; Anderson G
    Pharmacotherapy; 2017 Nov; 37(11):1469-1478. PubMed ID: 28805961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reference pricing for pharmaceuticals: is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?
    Faunce TA
    Med J Aust; 2007 Aug; 187(4):240-2. PubMed ID: 17564579
    [No Abstract]   [Full Text] [Related]  

  • 39. Medicaid drugs.
    Poisal JA
    Health Care Financ Rev; 2004; 25(3):1-4. PubMed ID: 15229992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What Determines How Much Your Patient Pays for Their Medication in the United States?
    Novack GD
    Am J Ophthalmol; 2016 Jul; 167():48-51. PubMed ID: 27131775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.